[Safety and Efficacy of Transcatheter Arterial Embolization for Renal Angiomyolipoma in Aichi Medical University Hospital].

We report on the safety and efficacy of transcatheter arterial embolization (TAE) for renal angiomyolipoma (AML) cases treated at our facility. A retrospective analysis was conducted on 48 cases of AML treated with TAE at our hospital between 2014 and 2022. The median follow-up period for imaging was 24 months (0-145 months), and that for blood tests was 19 months (0-117 months). Preventive renal artery embolization was performed in 36 cases, and emergency renal artery embolization was performed in 12 cases. The overall complication rate associated with embolization was 75% (36/48 cases), but there were no postoperative complications of Clavien-Dindo classification grade III or higher except for one case with blood transfusion, and there was no difference between the two groups. Renal function was evaluated by eGFR, and there was no difference in renal function changes before and after embolization between the two groups. Tumor reduction was observed in all cases, with no difference in tumor reduction effect. Reembolization was required in three cases after emergency renal artery embolization. TAE for rupture prevention significantly reduced rupture due to marked tumor reduction and did not result in a significant decline in renal function. Emergency TAE requires a prompt response and is more challenging, making the timing of preventive treatment crucial. With the improvement of embolic materials and techniques, the safety and efficacy of TAE have been increasing in facilities where TAE is feasible.